Returning search results with filters:
Remove filter forAudience: Healthcare
Remove filter forCategory: Drugs Clear all
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 485 items.
Diclofenac Sodium Micronized: Out of specification in the affected lot.
The Loss on Drying is out of specification in the affected lot.
RecallHealth product recall | 2023-03-21
ISTODAX (romidepsin) – Restricted Access Program
In 2013, ISTODAX (romidepsin) was authorized under a Notice of Compliance with conditions (NOC/c) for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one…
AlertHealth professional risk communication | 2023-03-20
Shortage of Nitroglycerin Sprays in Canada
Canada is experiencing a shortage of nitroglycerin 0.4 MG/ACT sprays due to supply issues with the raw materials used to make the sprays as well as an increase in demand. Nitroglycerin sublingual spray is applied under the tongue and is used to treat…
AlertPublic advisory | 2023-03-17
CAYSTON: Vials may be cracked in affected lots
Vials may be cracked in affected lots.
RecallHealth product recall | 2023-03-03
Heparin Sodium Injection: Out of Specification
Potential low Anti-Factor Ila potency out of specification.
RecallHealth product recall | 2023-03-01
Kirkland Signature Extra Strength Acetaminophen Tablets 500 mg: Out of Specification
The dissolution is out of specification in the affected lot.
RecallHealth product recall | 2023-02-17
ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting
Currently available data from the NOVA study, based on a data cut-off date of October 1, 2020, shows that the median OS may be lower with ZEJULA compared to placebo for patients in the overall non-gBRCAmut cohort and the non-gBRCAmut / Homologous…
AlertHealth professional risk communication | 2023-02-16
AG-BISOPROLOL: Foreign matter
The affected lot may contain the presence of foreign matter.
RecallHealth product recall | 2023-02-14
APO-AMITRIPTYLINE 10mg: NDMA Impurity
Affected lot exceeds concentration limit for N-nitrosodimethylamine (NDMA) at the 48-month stability testing timepoint.
RecallHealth product recall | 2023-02-07
Celestone Soluspan: Affected lots may contain the presence of foreign matter.
Affected lots may contain the presence of foreign matter.
RecallHealth product recall | 2023-01-31
RUZURGI (amifampridine) - Authorization Status
UPDATED INFORMATION – January 20, 2023 On January 10, 2023, following a Federal Court of Appeal decision, the June 24, 2021 decision of the Minister of Health on the application of the data protection provisions was restored, and a new Notice of…
AlertHealth professional risk communication | 2023-01-20
Belzer MPS and Belzer UW: Particulate matter
Presence of particulate matter in affected lot.
RecallHealth product recall | 2023-01-18
18F-Fludeoxyglucose (18F-FDG); Sterility concerns
Product sterility may be compromised in the affected lot.
RecallHealth product recall | 2022-12-14
The colour is out of specification in the affected lot(s).
RecallHealth product recall | 2022-12-06
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary Cholangitis (PBC)
OCALIVA received a Notice of Compliance with Conditions in May 2017 for the treatment of PBC, pending the results of trials to verify its clinical benefit. OCALIVA is now contraindicated for PBC patients with advanced disease, such as those with Child…
AlertHealth professional risk communication | 2022-12-05